RxDoctor Payments Data

Pooja Tandon, MD

Geriatric Psychiatry · Toms River, NJNPI 1922377258

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $701 and has fallen 98.2% since, to $13 in 2021.

$781in general payments, 2019–2025

Across 60 payments — averaging $13.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$114
  • Neurocrine Biosciences, Inc.$96
  • Acadia Pharmaceuticals Inc$86
  • Otsuka America Pharmaceutical, Inc.$78
  • AbbVie$76
  • Vanda Pharmaceuticals Inc.$65
  • plus $265 from 7 others

What the payments were for

  • Food & beverage$781100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$781 in reported general payments places this provider in the 70th percentile of 26 geriatric psychiatry providers in New Jersey.

See all geriatric psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$11,489
Medicare patients
39
Services billed
102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl21$30,481
RexultiBrexpiprazole13$18,878
Vilazodone Hcl33$3,227
Lurasidone Hcl14$3,113
Aripiprazole79$3,073
Quetiapine Fumarate111$1,485
Trazodone Hcl103$1,291
Duloxetine Hcl45$1,053
Buspirone Hcl72$1,051
Bupropion XlBupropion Hcl39$934
Venlafaxine Hcl ErVenlafaxine Hcl59$848
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$610
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$532
Quetiapine Fumarate ErQuetiapine Fumarate25$465
Sertraline Hcl56$415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$76$30,48121 claims
Otsuka America Pharmaceutical, Inc.Rexulti$78$18,87813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 26 geriatric psychiatry providers in New Jersey.

Other geriatric psychiatry in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →